A recent phase 3 trial showed that combining nivolumab with AVD chemotherapy improves 2-year progression-free survival while also offering a superior safety profile compared with a brentuximab vedotin...
A recent phase 3 trial showed that combining nivolumab with AVD chemotherapy improves 2-year progression-free survival while also offering a superior safety profile compared with a brentuximab vedotin...
Researchers report on the first safety and efficacy of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody, for patients with relapsed/refractory Mantle cell lymphoma. This study was presented at...
The OASIS trial evaluates the efficacy of ibrutinib, venetoclax, and obinutuzumab in newly diagnosed mantle cell lymphoma, reporting a 5-year progression-free survival (PFS) rate of 80% and overall survival...
Researchers analyzed data from a nationwide cohort to evaluate the effectiveness of covalent Bruton tyrosine kinase inhibitors, used either as monotherapy or in combination with anti-CD20 monoclonal...
A retrospective study highlights the safety and feasibility of outpatient administration of brexucabtagene autoleucel for patients with acute lymphoblastic leukemia and mantle cell lymphoma, showing...
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
Researchers examined the impact of protein-energy malnutrition on the risk of death in patients with diffuse large B-cell lymphoma who are undergoing chemotherapy.
